Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.
about
Vaccines for preventing herpes zoster in older adultsLipid A modification systems in gram-negative bacteriaScavenger Receptors: Emerging Roles in Cancer Biology and ImmunologyPotentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protectionAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesSuppression of antigen-specific CD4+ T cell activation by SRA/CD204 through reducing the immunostimulatory capability of antigen-presenting cellA structure-function approach to optimizing TLR4 ligands for human vaccinesRole of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.A deep rough type structure in Bordetella bronchiseptica lipopolysaccharide modulates host immune responses.Expression cloning and periplasmic orientation of the Francisella novicida lipid A 4'-phosphatase LpxF.Use of early passage fetal intestinal epithelial cells in semi-high-throughput screening assays: an approach to identify new innate immune system adjuvants.In situ photoimmunotherapy: a tumour-directed treatment for melanoma.Determination of pyrophosphorylated forms of lipid A in Gram-negative bacteria using a multivaried mass spectrometric approach.Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study.Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4.TLR-2 independent recognition of Mycobacterium tuberculosis by CD11c+ pulmonary cells from old miceCationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system.Helicobacter pylori versus the host: remodeling of the bacterial outer membrane is required for survival in the gastric mucosa.Structural characterization of bacterial lipopolysaccharides with mass spectrometry and on- and off-line separation techniques.TLR-based immune adjuvants.Discovery of new biosynthetic pathways: the lipid A story.Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid ANovel drugs targeting Toll-like receptors for antiviral therapy.Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptorsGLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults.Antigen-specific antibody responses in B-1a and their relationship to natural immunityComparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.From mice to humans - murine intelligence for human CD8+ T cell vaccine design.Update on toll-like receptor-directed therapies for human diseasePathological networking: a new approach to understanding COPD.Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine.Charting protein complexes, signaling pathways, and networks in the immune system.Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.Toll-like receptors and leishmaniasis.Toll-like receptor modulation in cardiovascular disease: a target for intervention?Comparison of Biological and Immunological Characterization of Lipopolysaccharides From Brucella abortus RB51 and S19.Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone.
P2860
Q24186050-351C53F9-638C-4120-B536-8D163FC95AADQ24650951-52371AB0-3F2A-43D5-BCC0-44A1263BF38EQ26799114-3AEDE48D-F112-44D1-83F4-2DB5CB9D7492Q27305883-65EA4C69-E0D5-4A01-85EA-C3D0AE1DDE1AQ27489000-6BB3FF68-CB8E-4D0C-9FB2-46D4C3772102Q28397011-BEC9D85F-B2F3-4E1F-9783-42659B975341Q28818147-17391459-1C50-4FE1-9B13-2B01DBDEE6E9Q30424747-BD168843-674E-4B84-A8F9-CD0CAB44D5B2Q31039926-FC7CDD75-9D0D-495E-8448-D800D3D51108Q33233454-C1EB461A-477E-4977-B0E8-E3C850AE5B52Q33254721-CBC8F4CC-4D6D-4E16-9298-6E177E00C57DQ33263668-ECCE8FFD-6128-42B8-8A73-ABB4F54EC206Q33364386-E5CE2DF5-95F6-4EB4-BAFD-30C11699E861Q33708801-D743E833-1710-440E-9B01-44EE49758C26Q33746872-9A5F7E60-D3C1-4411-86DF-9A9F66C4DF1CQ33903025-25818358-11CF-4DBC-8F84-B231629033DFQ33993559-6DD040D4-97C5-4B60-93AC-C773B850F124Q34012264-F4BEBB28-46B7-4CD4-9611-E8493574A635Q34034287-934668C8-3734-4472-A6AF-F4D767059889Q34116838-59C56FCC-35AF-4DEA-A310-F2CF1A0B5B98Q34312726-FDC34CEA-CD93-4027-9811-E1EFEE0BE100Q34400322-F031ACF2-01C7-4DF2-B49F-A83E0B1D8E39Q34599513-F7B17E8A-BF88-498B-A75D-3BC593445075Q34701875-9EDF9CD6-FE4C-475D-A878-246D95DB65C6Q34999938-A606AAB9-37BC-4E93-B67D-36E04C6BD5ACQ35220354-2F526F56-6549-4A07-B33E-9D5949F76C1DQ35669044-C888CCB0-DF1E-43A3-844E-E4FEB68E252BQ35887152-D34E7E47-03AE-40D9-B7ED-E51E6250833AQ35918838-3D741B21-C9B9-45AC-A262-A3354B1B35D9Q36065972-F6C5D73B-00A6-4E8F-876C-3B40028B9983Q36171745-E52D3AEE-DDAB-44AA-B34F-96D2FEF0D52CQ36225899-511A96FD-BEF4-4B1B-89C7-9CFE7C712F6EQ36257481-25689D0D-DE78-4A64-AA81-C36026493839Q36453373-EEA9614B-44CB-4E1F-8771-F4247EE766A5Q36465489-BBB43EB9-D478-4359-A745-D7BF2BE4F140Q36483521-3A505655-AD2F-4977-8D19-0BEFAF625CEEQ36543054-62F0A702-E3A2-40B2-BB62-CFCCCD6BD21AQ36543118-598F4B03-EEDF-4DF7-81EA-0281C867AB14Q36600380-28B34FEF-7F4C-4664-BFFB-0812353650FEQ36672533-71BF4325-4CDB-42C2-94BE-BED112DCC6C1
P2860
Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Taking a Toll on human disease ...... ts and monotherapeutic agents.
@ast
Taking a Toll on human disease ...... ts and monotherapeutic agents.
@en
type
label
Taking a Toll on human disease ...... ts and monotherapeutic agents.
@ast
Taking a Toll on human disease ...... ts and monotherapeutic agents.
@en
prefLabel
Taking a Toll on human disease ...... ts and monotherapeutic agents.
@ast
Taking a Toll on human disease ...... ts and monotherapeutic agents.
@en
P2093
P2860
P1476
Taking a Toll on human disease ...... ts and monotherapeutic agents.
@en
P2093
Christopher Cluff
David Johnson
David Persing
Jay T Evans
Jory R Baldridge
Patrick McGowan
Sally Mossman
P2860
P304
P356
10.1517/14712598.4.7.1129
P407
P577
2004-07-01T00:00:00Z